- Home
- TASK vs MNKD Comparison
TASK vs MNKD Comparison
Compare TASK & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TASK
- MNKD
- Stock Information
- Founded
- TASK 2008
- MNKD 1991
- Country
- TASK United States
- MNKD United States
- Employees
- TASK N/A
- MNKD N/A
- Industry
- TASK Retail: Computer Software & Peripheral Equipment
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- TASK Technology
- MNKD Health Care
- Exchange
- TASK Nasdaq
- MNKD Nasdaq
- Market Cap
- TASK 1.5B
- MNKD 1.7B
- IPO Year
- TASK 2021
- MNKD 2004
- Fundamental
- Price
- TASK $14.61
- MNKD $5.13
- Analyst Decision
- TASK Buy
- MNKD Strong Buy
- Analyst Count
- TASK 4
- MNKD 5
- Target Price
- TASK $16.88
- MNKD $10.80
- AVG Volume (30 Days)
- TASK 540.1K
- MNKD 3.9M
- Earning Date
- TASK 11-06-2025
- MNKD 11-06-2025
- Dividend Yield
- TASK N/A
- MNKD N/A
- EPS Growth
- TASK 21.25
- MNKD 149.32
- EPS
- TASK 0.67
- MNKD 0.11
- Revenue
- TASK $1,101,465,000.00
- MNKD $301,736,000.00
- Revenue This Year
- TASK $19.10
- MNKD $16.36
- Revenue Next Year
- TASK $11.73
- MNKD $20.34
- P/E Ratio
- TASK $22.31
- MNKD $50.23
- Revenue Growth
- TASK 19.04
- MNKD 21.48
- 52 Week Low
- TASK $10.57
- MNKD $3.38
- 52 Week High
- TASK $19.60
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- TASK 14.87
- MNKD 43.96
- Support Level
- TASK $16.78
- MNKD $5.33
- Resistance Level
- TASK $17.94
- MNKD $5.90
- Average True Range (ATR)
- TASK 0.43
- MNKD 0.24
- MACD
- TASK -0.33
- MNKD -0.07
- Stochastic Oscillator
- TASK 6.38
- MNKD 2.86
About TASK TaskUs Inc.
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to the world-wide Game-changing companies, helping its clients represent, protect and grow their brands. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.